<HashMap><database>MetabolomicsWorkbench</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>http://www.metabolomicsworkbench.org/rest/study/study_id/ST000851/mwtab</Other></files><type>primary</type></body><statusCodeValue>200</statusCodeValue><statusCode>OK</statusCode></file_versions><scores/><additional><omics_type>Metabolomics</omics_type><technology_type>Mass Spectrometry</technology_type><technology_type>ESI</technology_type><disease>Spinal Cord Injury</disease><species>Mus Musculus</species><full_dataset_link>http://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&amp;StudyID=ST000851</full_dataset_link><study_factor>time pt:P90d | grouping:K6-/-</study_factor><study_factor>time pt:P60d | grouping:Wt</study_factor><study_factor>time pt:P90d | grouping:K6+/+</study_factor><study_factor>time pt:P21d | grouping:K6-/-</study_factor><study_factor>time pt:P21d | grouping:PAR1</study_factor><study_factor>time pt:P21d | grouping:PAR2</study_factor><study_factor>time pt:P21d | grouping:CTRL</study_factor><study_factor>time pt:P21d | grouping:K6+/+</study_factor><study_factor>time pt:P60d | grouping:PAR1-/-</study_factor><study_factor>time pt:P60d | grouping:PAR2-/-</study_factor><tissue>Spinal Cord</tissue><submitter_affiliation>Mayo Clinic</submitter_affiliation><sample_protocol>Reversed phase POSITIVE ION MODE.</sample_protocol><repository>MetabolomicsWorkbench</repository><metabolite_name>SPA</metabolite_name><metabolite_name>C18:1-cer</metabolite_name><metabolite_name>C16-cer</metabolite_name><metabolite_name>C8-cer</metabolite_name><metabolite_name>C18-cer</metabolite_name><metabolite_name>Sph</metabolite_name><metabolite_name>C20-cer</metabolite_name><metabolite_name>C22-cer</metabolite_name><metabolite_name>C18-dh cer</metabolite_name><metabolite_name>C24-cer</metabolite_name><metabolite_name>C16-dh cer</metabolite_name><metabolite_name>S1P</metabolite_name><metabolite_name>C18:1-dh cer</metabolite_name><metabolite_name>C24:1-cer</metabolite_name><metabolite_name>C14-cer</metabolite_name><data_protocol></data_protocol><name_synonyms>PAR, pbp2, par1, sphingolipids, CG8201, F7D19.13, SXR, Sheath, f2r-a, PRR, dPAR1, dPar1, ThrR, dMARK, AI482343, DmelCG8201, ONR1, CF2R, CG11960, ctak1, CG30131, CG30132, EMK, F7D19_13, dPAR-1, D15Ertd747e, anon-WO0210402.19, DPAR-1, PARq, dPar-1, GPCR42, Function Recovery, SNQ3, BXR, 27C1, SAR, Lysosphingolipids, HTR, Gpr172b, PXR, HLH1, l(2)k06323, Sheaths, Function Recoveries., mRFT1, Gpcr11, Cf2r, par-1, c-tak1, PAR-2, emk1, HELIX-LOOP-HELIX 1, PAR-1, Myelin, l(2)27C1, emk-1, GPR11, Sphingolipid, BcDNA:RH48823, par1b, emk-2, 2010003P03Rik, MARK, Par-1, DPar1, Par-1A, Par-2, PAR2, Par2, PAR1, Par1, Myelin Sheaths, CG16701, PHY RAPIDLY REGULATED 1, TR</name_synonyms><sample_synonyms>backward, reversed.</sample_synonyms></additional><is_claimable>false</is_claimable><name>Targeting Myelin Sphingolipids of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI</name><description/><dates><publication></publication></dates><accession>ST000851</accession><cross_references><TAXONOMY>10090</TAXONOMY></cross_references></HashMap>